ERBB2 and aneurysmal bone cyst: The open-label, single-group, multi-centre, phase II DESTINY BREAST 01 study evaluated T-DXd in 184 patients with HER2-positive ABC with previous treatment with trastuzumab and T-DM1 and a median of six prior lines of therapy, and confirmed the remarkable activity observed in phase I [22].